Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

BusinesswireNov 26 08:45 ET

Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

ReutersNov 26 08:45 ET

Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

ReutersNov 19 08:00 ET

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 8 19:23 ET

Lantern Pharma Advances AI-Driven Cancer Therapies

TipRanksNov 7 23:48 ET

Lantern Pharma Reports Q3 EPS (42c), One Estimate (56c)

TipRanksNov 7 16:26 ET